China’s caffeine war: Fast-growing Luckin brews up a threat to Starbucks
July 24, 2018
Stock futures rise as Alphabet gains, lifts FAANG stocks
July 24, 2018

Biogen beats estimates on Spinraza sales, raises forecast

Biogen Inc reported a better-than-expected quarterly profit on Tuesday and raised its forecast for 2018 adjusted earnings, driven by strong demand for its spinal muscular atrophy drug Spinraza, sending its shares up 3 percent.

Powered by WPeMatico